| scholarly article | Q13442814 |
| P2093 | author name string | P. D. James | |
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2006-08-10 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study |
| Q36822738 | A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture |
| Q34909055 | A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease |
| Q47350762 | Advances in the diagnosis and treatment of Von Willebrand disease |
| Q49989077 | Advances in the diagnosis and treatment of Von Willebrand disease. |
| Q35018544 | An apparently silent nucleotide substitution (c.7056C>T) in the von Willebrand factor gene is responsible for type 1 von Willebrand disease |
| Q39286115 | Angiodysplasia in von Willebrand Disease: Understanding the Clinical and Basic Science |
| Q83025477 | Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized |
| Q37175593 | Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications. |
| Q36743353 | Cellular and molecular basis of von Willebrand disease: studies on blood outgrowth endothelial cells |
| Q36369902 | Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease |
| Q41810258 | Characterization of aberrant splicing of von Willebrand factor in von Willebrand disease: an underrecognized mechanism |
| Q30535420 | Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes |
| Q36920462 | Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States |
| Q43137286 | Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease |
| Q34873778 | Clinical utility gene card for: von Willebrand disease |
| Q34022444 | Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor |
| Q30411744 | Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project |
| Q57094753 | Common sequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD |
| Q30555005 | Critical von Willebrand factor A1 domain residues influence type VI collagen binding |
| Q41620644 | Current and Emerging Options for the Management of Inherited von Willebrand Disease. |
| Q57095004 | Current issues in diagnosis and treatment of von Willebrand disease |
| Q37324147 | De novo mutation and somatic mosaicism of gene mutation in type 2A, 2B and 2M VWD. |
| Q39027896 | Diagnosing von Willebrand disease: genetic analysis |
| Q38814362 | Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24. |
| Q34336631 | Effect of genetic variation in STXBP5 and STX2 on von Willebrand factor and bleeding phenotype in type 1 von Willebrand disease patients. |
| Q47416217 | Evaluation of a microfluidic flow assay to screen for von Willebrand disease and low von Willebrand factor levels |
| Q57824128 | Evaluation of a semi-automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers |
| Q42664083 | Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L. |
| Q34310576 | Functional characterization of a 13-bp deletion (c.-1522_-1510del13) in the promoter of the von Willebrand factor gene in type 1 von Willebrand disease. |
| Q34667787 | Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. |
| Q93092084 | Genetic Variation in the von Willebrand Factor Gene in Swedish von Willebrand Disease Patients |
| Q37349860 | Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage |
| Q91675224 | Genetic regulation of plasma von Willebrand factor levels in health and disease |
| Q34663589 | Genetic sequence analysis of inherited bleeding diseases |
| Q35037432 | Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis |
| Q37351431 | Genome-wide association studies identify genetic loci for low von Willebrand factor levels |
| Q35577026 | Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders |
| Q35859255 | Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease |
| Q36658007 | Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). |
| Q99631229 | Improving diagnosis of von Willebrand disease: Reference ranges for von Willebrand factor multimer distribution |
| Q41808379 | Intracellular storage and regulated secretion of von Willebrand factor in quantitative von Willebrand disease |
| Q37576572 | Laboratory testing for von Willebrand disease: toward a mechanism-based classification |
| Q97551370 | Low VWF: insights into pathogenesis, diagnosis, and clinical management |
| Q30433859 | Modifiers of von Willebrand factor identified by natural variation in inbred strains of mice |
| Q47165791 | Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): comprehensive genetic analysis by next-generation sequencing of 480 patients. |
| Q37602557 | Molecular testing for disorders of hemostasis |
| Q36417697 | New insights into genotype and phenotype of VWD. |
| Q39027900 | New treatment approaches to von Willebrand disease. |
| Q36814657 | No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation |
| Q33817075 | Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium |
| Q47793791 | Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels |
| Q38258281 | Of von Willebrand factor and platelets |
| Q34923853 | Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models |
| Q37703427 | Perils, problems, and progress in laboratory diagnosis of von Willebrand disease |
| Q42337433 | Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort |
| Q28607764 | Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF |
| Q49246959 | Regulation of plasma von Willebrand factor. |
| Q45871569 | The Association of Aging With Von Willebrand Factor Levels and Bleeding Risk in Type 1 Von Willebrand Disease. |
| Q37043558 | The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels |
| Q64890963 | The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity. |
| Q37524379 | The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles |
| Q42743025 | The molecular basis of von Willebrand disease: the under investigated, the unexpected and the overlooked |
| Q26996413 | The molecular characterization of von Willebrand disease: good in parts |
| Q37193881 | The molecular genetics of von Willebrand disease |
| Q34185963 | Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report. |
| Q37602563 | Translational medicine advances in von Willebrand disease |
| Q35849223 | VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population |
| Q37253917 | Von Willebrand disease in the United States: a perspective from Wisconsin |
| Q58781583 | Von Willebrand disease in the elderly: clinical perspectives |
| Q28742241 | Von Willebrand disease: an overview |
| Q30240214 | What have we learned from large population studies of von Willebrand disease? |
| Q85963378 | [The research progress of Von Willebrand disease] |
| Q55053921 | von Willebrand disease. |
| Q37635167 | von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy |
| Q26863636 | von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies |
| Q36143225 | von Willebrand factor propeptide: biology and clinical utility |
| Q37376222 | von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels. |
Search more.